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ABSTRACT
Upregulation of Translationally Controlled Tumor Protein (TCTP) is associated 
with poorly differentiated aggressive tumors, including breast cancer, but the 
underlying mechanism(s) are still debated. Here, we show that in breast cancer cell 
lines TCTP is primarily localized in the nucleus, mostly in the phosphorylated form.
The effects of Dihydroartemisinin (DHA), an anti-malaria agent that binds TCTP, 
were tested on breast cancer cells. DHA decreases cell proliferation and induces 
apoptotic cell death by targeting the phosphorylated form of TCTP. Remarkably, DHA 
enhances the anti-tumor effects of Doxorubicin in triple negative breast cancer cells 
resulting in an increased level of apoptosis. DHA also synergizes with Trastuzumab, 
used to treat HER2/neu positive breast cancers, to induce apoptosis of tumor cells.
Finally, we present new clinical data that nuclear phospho-TCTP overexpression 
in primary breast cancer tissue is associated with high histological grade, increase 
expression of Ki-67 and with ER-negative breast cancer subtypes. Notably, phospho-
TCTP expression levels increase in trastuzumab-resistant breast tumors, suggesting 
a possible role of phospho-TCTP as a new prognostic marker.
In conclusion, the anti-tumor effect of DHA in vitro with conventional 
chemotherapeutics suggests a novel therapeutic strategy and identifies phospho-
TCTP as a new promising target for advanced breast cancer.
INTRODUCTION
Breast cancer is the most common cancer found in 
women. Many therapies have been shown to be effective 
in specific subsets of breast cancer patients. Nevertheless, 
the progression of this disease towards metastasis is 
a long-standing problem that requires more selective 
approaches.
Gene expression analysis of primary breast 
tumors provided important indications that some genetic 
properties inherent to the primary tumor might predispose 
cancer cells towards a more aggressive phenotype [1, 2]. 
The characterization of these genes could have important, 
potentially therapeutic, implications for identifying tumors 
at high risk of progression early on.
However, one limitation of these studies is that some 
genes or signaling pathways which underlie the molecular 
traits of an aggressive phenotype might be not oncogenes 
or mutated in cancer cells, and would therefore need to 
be identified using a different approach. One example is 
the Kruppel-like transcription factor KLF4/GKLF whose 
nuclear localization is a prognostic factor of an aggressive 
phenotype in the early-stages of infiltrating ductal breast 
carcinoma [3].
All of these studies suggest that the rational way to 
improve the current risk classification system at primary 
diagnosis is to compare and, eventually, combine all 
the information from genomic, proteomic and immu-
nohistochemical studies with the clinico-pathological 
factors.
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In this context, the characterization of novel 
biomarkers implicated in tumor progression provides 
new opportunities for combining therapies with classical 
chemotherapeutics.
Recently, it has been reported that upregulation of 
TCTP is correlated with poorly differentiated tumors, 
including breast cancer [4–7], thus highlighting its 
potential as biomarker for prognosis. TCTP is a highly 
conserved protein that exhibits pleiotropic biological 
functions [8, 9]. Gene knockout studies have revealed 
that TCTP-deficient mice and TCTP-deficient mutants 
of Drosophila die in the early stages of embryogenesis 
suggesting its role in cell survival mechanisms [10, 11]. 
It has been reported that TCTP has the properties of a 
tubulin-binding protein [12–14] that dynamically interacts 
with microtubules during the cell cycle [14]. In addition, 
it has also been demonstrated that TCTP is a key mitotic 
target of Polo-like kinase1 (Plk1), a serine/threonine 
kinase, which plays an important role through TCTP for 
regulating anaphase progression [15, 16]. When PLK1 
phosphorylation sites on TCTP are blocked a dramatic 
increase in apoptotic cells is observed, suggesting that 
the completion of mitosis is inhibited [16]. TCTP has also 
been described as an anti-apoptotic factor [4, 17–19]. We 
previously demonstrated that TCTP is a survival factor that 
protects breast cancer cells from oxidative stress-induced 
cell death. Its inhibition reduces tumor cell growth, re-
establishes sensitivity to environmental stress and lowers 
the apoptotic threshold. We proposed TCTP as a “stress 
hallmark” that may be exploited as a therapeutic target 
to decrease the resistance of cancer cells to anticancer 
therapy [20].
Since drug development is time-consuming and 
costly [21, 22], we identified a TCTP inhibitor among 
drugs that had already been tested for toxicity in humans, 
such as Dihydroartemisinin (DHA). DHA is a metabolite 
of Artemisinin, the active principle of Artemisia annua. 
DHA is an anti-malaria agent that also demonstrates 
anticancer activity [23–25]. It has recently been proven 
that DHA binds human TCTP and reduces the intracellular 
TCTP levels via ubiquitination and subsequent 
proteasome-mediated degradation in many tumor cell 
lines [26].
The objective of this study was to assess whether 
TCTP inhibition by DHA may affect the growth of breast 
cancer with less responsive behavior. In particular, we 
asked if TCTP or any post-translational modifications 
of TCTP may be correlated with enhanced tumor 
aggressiveness in breast cancer cells and if it could be 
affected by the DHA treatment. We also investigated 
whether the reduction of TCTP induced by DHA would 
increase the sensitivity of breast cancer cells to drug 
treatment. Here we show that the reduction by DHA of 
phospho-TCTP expression levels is critical in breast 
cancer cell growth and survival. Moreover, we present 
new clinical data that high phospho-TCTP levels are 
correlated with high grade tumors, increase expression of 
Ki-67 and with ER-negative breast cancer subtypes.
These data suggest that phospho-TCTP expression 
is correlated with enhanced tumor aggressiveness and 
provide a novel strategy to target advanced breast cancer.
RESULTS
Antitumor efficacy of DHA
The antitumor effect of DHA treatment on breast 
cancer cell lines and TCTP expression levels was 
investigated at concentrations of 20 and 50 μM which, 
when previously tested on human peripheral blood 
mononuclear cells from healthy donors, had shown no 
cytotoxicity (data not shown).
Following the molecular classification for breast 
carcinoma [27, 28], we chose the MDA-MB-231 cell 
line with a basal-like phenotype, and the SKBR3, HER2-
positive cell line. These cell lines represent in vitro 
models for studying oestrogen receptor (ER)-negative 
tumors with an aggressive natural history [29, 30]. 
Exponentially growing MDA-MB-231 (hereafter called 
MDA) and SKBR3 cells were cultured in the presence or 
absence of DHA. The number of viable cells, evaluated 
by ATP (Figures 1A and 1B, upper panels) and trypan 
blue dye exclusion assays (Figure 1A and 1B, lower 
panels), decreased severely during the treatment period as 
compared to untreated cells. Furthermore, a progressive 
reduction of proliferating cells was observed in cell 
cultures when exposed to DHA for 6 days. This effect 
was not reversed when DHA was removed from the cell 
cultures during the last 3 days. In addition, when the long-
term cell cultures (6-days) received a second dose of DHA 
at day 3, a further reduction in cell viability was observed 
at day 6, confirming the sensitivity of both cell lines to 
DHA treatment (Figure 1C).
We then investigated the effect of DHA on TCTP 
mRNA and protein expression. RT-PCR analysis showed 
that mRNA levels were unaffected in MDA treated cells 
(1.38 ± 0.41 and 2.33 ± 0.73 mRNA fold increase versus 
control cells at 20 and 50 μM DHA respectively; data not 
shown).
In contrast, TCTP protein levels were almost 
unchanged at 24 h, but were greatly reduced in MDA 
cells treated for 48 h with 50 μM DHA (Figure 1D), 
indicating the inhibitory effect of DHA on TCTP 
protein expression levels, as previously reported [26, 
31]. However, a slight increase of TCTP levels was 
observed after 72 h, likely due to the DHA short half-
life as reported by in vivo [32] and in vitro studies [33, 
34] which suggest that DHA may cause severe damage 
during the first hours of exposure in breast cancer cells. 
Similar results were also obtained in SKBR3 cells treated 
with 50 μM DHA (Figure S1B–C).
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Figure 1: DHA reduces cell viability and TCTP expression levels in MDA and SKBR3 cells. MDA (A) and SKBR3 cells 
(B) were treated with 20 (----) and 50 μM (–) DHA for 24, 48 and 72 h. At the end of incubation time, the number of viable cells was 
determined using ATP-assay (upper panels) and trypan blue dye exclusion assay (lower panels). Data are expressed as the percentage of 
viable cells relative to controls. Values represent the mean ± SD, n = 3. Significant differences between treated and control cells, at any time 
of treatment, are indicated, ** = p < 0.01, *** = p < 0.001. (C) Exponentially growing MDA and SKBR3 cells were cultured for 6 days and 
treated with 50 μM DHA (panel C, left): 1) cells were exposed to DHA for 6 days; 2) cells were exposed to DHA for 3 days and then the 
drug was removed; 3) on day 3 cells were washed with fresh media and treated again with 50 μM DHA for 3 days. Data are expressed as 
the percentage of viable cells relative to controls. Values represent the mean ± SD, n = 3. (D) Western Blot analysis of TCTP in cell lysates 
of MDA cells after 24, 48 and 72 h of exposition to DHA. β-actin was used as loading control.
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DHA induces a strong reduction of phospho-
TCTP levels
Since we did not observe any remarkable reduction 
of TCTP expression levels during the first 24 h of 
treatment, when DHA was already highly effective on 
cell viability, we asked whether any post-translational 
modifications of TCTP might be affected by the DHA 
treatment.
Recent studies have demonstrated that TCTP is an 
important downstream signalling component of Polo-like 
Kinase 1 (PLK1); moreover, phosphorylation of TCTP 
by PLK1 promotes its localization in the nucleus [15, 
16]. As shown in Figure 2A and Figure S1A, TCTP is 
phosphorylated in both MDA and SKBR3 cells. Phospho-
TCTP expression levels were reduced by treatment with BI 
2536, a selective PLK1 inhibitor [35, 36], confirming that 
TCTP is phosphorylated by PLK1 in mammary carcinoma 
cells. The reduction of phospho-TCTP expression levels 
was also correlated with the inhibition of cell viability 
(Figure 2B), suggesting that TCTP phosphorylation by 
PLK1 is a critical event in the regulation of cell growth.
In order to investigate the localization of phospho-
TCTP, we carried out a sub-cellular localization 
analysis. Figure 2C and Figure S1B show that the TCTP 
was primarily localized in the nucleus, mostly in the 
phosphorylated form. When cells were treated with 50 
μM DHA for 24 h, we observed a dramatic reduction of 
phospho-TCTP expression levels. In addition, the reduction 
of phospho-TCTP expression levels was maintained at 48 
and 72 h in both cell lines (Figure 2D and Figure S1C).
Since it has been reported that the reduction of 
phospho-TCTP activity leads to a mitotic catastrophe and 
cell death [16] we studied the activation of caspases 3/7 
in DHA-treated cells. The results showed a significant 
increase of caspases 3/7 activity in DHA-treated cells 
(Figure 2E) consistent with apoptotic cell death.
A previous study demonstrated that DHA 
irreversibly down-regulates c-Myc protein in various 
human tumor cell lines [37]. As shown in Figure 2C and 
in Figure S1B, DHA had no notable effect on c-Myc 
expression levels during the first 24 h of treatment. This 
suggests that the cellular response to DHA was not related 
to c-Myc protein expression levels but rather, was strictly 
associated with the reduction of phospho-TCTP expression 
levels.
The relevance of phospho-TCTP expression was 
also investigated in MCF7 and in BT-474, two human 
breast cancer cell lines, which closely resemble the luminal 
A and luminal B oestrogen receptor (ER)-positive tumors, 
respectively [29, 30]. Western Blot analysis of the nuclear 
and cytoplasmic fractions showed a lower expression of 
phospho-TCTP in BT-474 cells compared to MCF7 cells 
(Figure S2A). As the BT474 cell line is derived from a 
primary invasive ductal carcinoma, while the MCF7 
cell line is derived from a metastatic invasive ductal 
carcinoma, these data strongly suggest that phospho-TCTP 
expression levels may be associated with enhanced tumor 
aggressiveness. Phospho-TCTP and TCTP expression 
levels were dramatically reduced (Figure S2B) and cell 
proliferation was decreased, in a dose-dependent manner, 
after 72h of DHA treatment (Figure S2C). Moreover, DHA 
induced a caspase-dependent apoptosis as indicated by 
activation of the caspases 3 and 7 (Figure S2D).
We then investigated whether the ubiquitin-
proteasome pathway may regulate the turnover of TCTP 
in MDA cells during the first 24 h of exposure to DHA. As 
shown in Figure 2F, DHA induced the ubiquitination and 
subsequent degradation of TCTP, as previously reported 
[26]. This suggest that the ubiquitineted-TCTP proteins 
may not be recognized by PLK1, therefore, causing a 
reduction in phopho-TCTP levels (Figure 2G).
TCTP knock down in MDA cells enhances DHA 
cytotoxicity
To further test the cytotoxicity of DHA in tumor 
cells with low TCTP expression levels, we knocked 
down TCTP gene expression in MDA cells using RNA 
interference.
The expression of TCTP was substantially reduced 
by specific siRNA as compared to scrambles siRNA 
(Figure 3A, left panel). Remarkably, in TCTP silenced 
cells, we observed enhanced cytotoxicity of DHA after 
48 h as indicated by cell viability assay (Figure 3A, 
right panel) and by increase in activated caspase 3 levels 
(Figure 3A, left panel), hence indicating that additional 
mechanisms, such as oxidative stress [24, 38], may also 
mediate cytotoxicity of DHA.
DHA shows low cytotoxicity in the non-
tumorigenic human mammary cell line MCF 10A
We further investigated the cytotoxicity of DHA 
in MCF 10A, a human breast epithelial cell line, which 
expresses relatively low phospho-TCTP and TCTP levels 
in comparison to MDA cells, as shown by Western Blot 
analysis (Figure 3B) and immunofluorescence staining 
(Figure 3C). DHA reduced both phospho-TCTP and 
TCTP expression levels (Figure 3B) and cell viability 
(Figure 3D). However, DHA exerted a lower cytotoxicity 
in MCF 10A compared to MDA cells, as indicated by the 
level of caspase 3/7 activation (Figure 3E). Interestingly, 
c-Myc levels were greatly reduced in MCF 10A-treated 
cells (Figure 3B).
Overexpression of phospho-TCTP rescues TCTP 
knockdown phenotype
We then investigated the ability of phospho-TCTP 
to rescue the TCTP knockdown phenotype. We used 
the easy-to-transfect human HeLa cell line as model for 
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Figure 2: DHA reduces phospho-TCTP levels. (A) Western Blot analysis of indicated proteins in cell lysates of MDA cells treated 
with 10 and 20 nM BI 2536 for 48 h. β-actin was used as loading control. (B) MDA and SKBR3 cells were treated with 10 and 20 nM 
of BI 2536 for 48 h. At the end of incubation time, the number of viable cells was determined by trypan blue dye exclusion assay. Data 
are expressed as the percentage of viable cells relative to controls. Values represent the mean ± SD, n = 3. (C) Subcellular localization of 
indicated proteins in MDA cells. MDA cells were treated with 50 μM DHA for 24 h. Nuclear and cytoplasmic fractions of untreated and 
treated cells were analyzed by Western Blot analysis for the indicated proteins. Lamin A/C and Tubulin were used as loading controls for 
nuclear and cytoplasmic fractions, respectively. (D) Western Blot analysis of indicated proteins in MDA cells after 48 and 72 h of exposition 
to 50 μM of DHA. β-actin was used as loading control. (E) Caspase-3/7 activity (normalized to cell number) was evaluated as a marker 
of apoptosis in MDA and SKBR3 cells after 24, 48 and 72 h of exposition to 50 μM of DHA. Data are expressed as arbitrary units. Values 
represent the mean ± SD, n = 3. * = p < 0.05. (F) MDA cells were treated for 24 h with two different concentrations of DHA (20 and 50 
μM). Cell lysates (1 mg protein) were immunoprecipitated with a polyclonal anti-ubiquitin antibody, followed by immunoBlotting with an 
anti-TCTP antibody. (G) Cell lysate (10 μg) were analyzed by Western Blot analysis for the indicated proteins. β-actin was used as lysate 
input loading control (lower panel).
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Figure 3: Effect of DHA in TCTP-silenced MDA cells and in the non-tumorigenic human mammary cell line MCF 10A 
with low TCTP expression levels. (A) MDA cells were transfected with a scrambled siRNAs (si ctr) or with siRNAs targeting TCTP 
(si TCTP). Cells were treated with 50 μM of DHA for 48 h. Western Blot analysis of indicated proteins. β-actin was used as loading control 
(left panel). The number of viable cells was determined by trypan blue dye exclusion assay at the end of incubation time (right panel). Data 
are expressed as the percentage of viable cells relative to controls. Values represent the mean ± SD, n = 4. *** = p < 0.001. (B) Western 
Blot analysis of indicated proteins in MDA and MCF 10A cells after 48 h of exposition to 50 μM DHA. β-actin was used as loading control. 
(C) Immunofluorescence detection of TCTP. Cells were analysed by immunofluorescence. Nuclei were stained with 4’,6-diamidino-2-
phenylindole (DAPI). TCTP and phospho-TCTP was detected with specific antibodies. The overlay of the two fluochromes is shown 
(Merge). Images were captured with a LEICA Confocal Laser Scanning Microscopy TCS SP5 system, equipped with a 40x oil immersion 
objective. Bar = 10 μm. Data from a representative experiment of two with similar results are shown. (D) Cytotoxicity of DHA in MCF 10A 
cells. Cells were treated with 50 μM DHA for 24, 48 and 72 h. At the end of incubation time, the number of viable cells was determined 
using ATP-assay (upper panel) and trypan blue exclusion assay (lower panel). Data are expressed as the percentage of viable cells relative 
to controls. Values represent the mean ± SD, n = 3. (E) Caspase-3/7 activity (normalized to cell number) was evaluated as a marker of 
apoptosis in MCF 10A cells. Cells were treated as described in the legend 3D. Data are expressed as arbitrary units. Values represent the 
mean ± SD, n = 3.
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gain-and-loss-of-function experiments. First, we generated 
TCTP knockdown HeLa cells (Figure 4A). These 
cells were more sensitive to DHA treatment compared 
to control cells as indicated by cell viability assay 
(Figure 4B). Then, TCTP silenced-cells were transiently 
transfected with a plasmid encoding Flag tagged wild-
type TCTP (WT) or a mutant lacking two serine residues 
46 and 64 (AA). As shown in Figure 4C, TCTP-silenced 
cells transfected with the WT-TCTP or with the AA-
TCTP constructs expressed high levels of TCTP proteins, 
indicating that the TCTP-specific shRNA stably expressed 
in TCTP-silenced cells was able to suppress the basal 
level of endogenous TCTP, but was unable to prevent 
exogenous protein overexpression. The exogenous Flag-
tagged WT-TCTP or AA-TCTP levels were not reduced by 
DHA treatment. However, only the overexpression of WT-
TCTP was able to rescue cells from the cytotoxic effect 
of DHA, while AA-TCTP overexpression cannot rescue 
the TCTP knockdown phenotype, as indicated by cells 
viability assay (Figure 4D).
DHA enhances sensitivity to chemotherapy
In order to determine whether the inhibition of 
phospho-TCTP activity may enhance the sensitivity of 
breast cancer cells to anti-cancer drugs, we studied the 
effect of therapeutic agents in MDA and SKBR3 cell lines 
pre-treated with 50 μM DHA for 24 h. Cell viability was 
measured after a subsequent 48 h treatment with three 
different chemotherapy drugs: Doxorubicin, Cisplatin 
and Paclitaxel. When combined with DHA, Doxorubicin 
(5 μM) and Cisplatin (50 μM) were more effective in 
inhibiting the growth of MDA cells compared to the effect 
induced by each agent alone (Figure S3A). No additional 
effect was observed by adding Paclitaxel to DHA 
treatment (data not shown). Notably, the combination of 
Figure 4: Overexpression of TCTP rescues TCTP knockdown phenotype in HeLa cells. (A) HeLa cells expressing TCTP-
shRNA plasmids (shTCTP) or control-shRNA plasmids were treated for 24 h with 50 μM of DHA. Western Blot analysis of indicated 
proteins. β-actin was used as loading control. Results from untreated HeLa cells and HeLa ctr-shRNA gave superimposable results and are 
indicated as control HeLa cells (shCtr). (B) Cells were treated with 50 μM of DHA for 24 h. The number of viable cells was determined 
by trypan blue dye exclusion assay at the end of incubation time. Data are expressed as the percentage of viable cells relative to controls. 
Values represent the mean ± SD, n = 3. (C) TCTP silenced-cells were transiently transfected with a plasmid encoding Flag tagged wild-type 
TCTP (WT) or a mutant lacking two serine residues 46 and 64 (AA). Mock-transfected cells were used as control (vector). After 24 h, cells 
were treated with DHA (50 µM). A Western Blot analysis was carried out after 24 h of exposure to DHA. (D) Cells were treated as in legend 
4C. The number of viable cells was determined by trypan blue dye exclusion assay at the end of incubation time. Data are expressed as the 
percentage of viable cells relative to controls. Values represent the mean ± SD, n = 3.
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Doxorubicin with DHA showed a great inhibition of cell 
proliferation even at lower doses of Doxorubicin (1 μM; 
Figure 5A) and induced a significant increase of apoptosis 
(Figures 5B and 5C). This drug combination in MDA 
cells resulted in synergistic effect with CI of 0.661 ± 0.33 
(Table S1).
Similar results were obtained when SKBR3 cells 
were subjected to the same drug treatments (Figure S3B); 
however, the DHA-combinatorial approach was not 
efficacious at 1 μM Doxorubicin (data not shown).
We then investigated the effect of Trastuzumab in 
combination with DHA in SKBR3 cells. Trastuzumab 
(Herceptin) is a mAb widely used for HER2-positive 
breast cancers. Following the protocol described in legend 
5A, we observed only a slight decrease of cell viability by 
combining of DHA and Trastuzumab (Figures S4A and 
S4B). Strikingly, a strong inhibitory effect was observed 
when cells were exposed to a lower concentration of DHA 
(20 μM) and then treated with Trastuzumab for 6 days 
(Figure 5D). Moreover, the combination of DHA with 
Trastuzumab induced a significant increase of apoptosis 
as evaluated by the activation of caspase 3/7 (Figure 5E) 
and by the amount of cleaved- PARP (c-PARP, Figure 5F). 
The CI value for this drug combination was 1.070 ± 0.2, 
indicating an additive effect of the two drugs (Table S2). 
In addition, the expression of HER2 was not affected by 
DHA suggesting that this drug does not alter the sensitivity 
of HER2 positive cells to mAb therapy (Figure 5F).
Correlation between high phospho-TCTP 
expression and high grade breast tumors
To study the clinical relevance of phospho-TCTP 
expression in human mammary carcinoma, we performed 
an immunohistochemistry analysis of phospho-TCTP in 
85 human breast cancer specimens.
The association between the clinicopathological 
characteristics and phospho-TCTP expression is shown 
in Table 1. Phospho-TCTP expression was not correlated 
with the patient’s age or tumor size (p > 0.05) but it was 
positively associated with the pathological grade (p < 
0.005). In all grade I cases phospho-TCTP expression was 
always ≤ 1%, while in grade II or III tumors phospho-
TCTP expression was always > 1%. Interestingly, only 
5% of grade II or III cases showed a low phospho-TCTP 
level (1–3%). High phospho-TCTP expression was found 
in ER-negative breast cancer subtypes which often have 
a worse prognosis (p = 0.022). Moreover, it was also 
positively associated with cell proliferation as indicated by 
the increase in Ki-67 (p = 0.019), lymph node (p = 0.032) 
and HER2 status (p = 0.021).
High phospho-TCTP levels were observed only in 
breast cancer tissues (Figure 6B–6F) as compared to the 
adjacent normal breast tissues (Figure 6A). In addition, 
we found a predominantly nuclear staining of phospho-
TCTP in high-grade tumors (grades II or III) consistent 
with the in vitro data (Figure 6C and 6D). Notably, 
among 35 patients treated with trastuzumab therapy we 
observed high expression of phospho-TCTP (> 10%) 
when tumors showed resistance to trastuzumab therapy 
(p < 0.005) (Figure 6E and 6F, and Table 2).
DISCUSSION
We previously reported that the expression of TCTP 
in tumor cells is linked to stress-response mechanisms 
and demonstrated that the reduction of TCTP protein 
expression is critical for tumor growth/survival. Thus 
we proposed TCTP as a “stress hallmark” that may be 
exploited as a therapeutic target to decrease the resistance 
of tumor cells to therapy [20].
DHA, commonly used in malaria therapy, also 
shows anticancer activity [23–25]. The mechanism of 
DHA in tumor cells is still unclear. It has been proposed 
that highly reactive endoperoxide moiety is at least 
partially responsible for its anticancer activity [24, 38]. 
DHA’s primary activator involves an iron source, in the 
form of Fe+2 or heme, or both. The iron(II)-mediated 
ROS and/or carbon centered radicals can cause cell injury 
and death [24, 38–40]. Remarkably, the intracellular 
iron metabolism is altered in breast cancer cells, thereby 
making them more vulnerable to the cytotoxic effect of 
DHA [41].
Microarrray analysis reveals that many genes 
involved in the regulation of cell proliferation or survival 
are correlated with the cellular response to DHA [24]. 
However, it remains unclear whether the antitumor activity 
of DHA may be mediated by specific molecular targets: 
TCTP is one of the proposed targets for tumor cells [26, 
31] and plasmodia. [42–44]
Here, we provide evidence that in exponentially 
growing human breast cancer cells, with more aggressive 
phenotypes, phospho-TCTP is located mainly in the 
nucleus of the cells. The phospho-TCTP expression 
level is strongly reduced by DHA-treatment and is 
correlated with the cytotoxicity of DHA. The role of 
phospho-TCTP activity in growing cells is supported 
by the reduction of phospho-TCTP caused by BI 2536, 
a specific PLK1 inhibitor [35, 36]. PLK1 is a crucial 
serin/treonin kinase in regulating cell proliferation, 
whose overexpression has been observed in many 
tumors, including breast cancer [45]. It has been shown 
that PLK1 phosphorylates TCTP from the G2 phase to 
the telophase of the cell cycle, and promotes phospho-
TCTP nuclear and perichromosomal localization both 
in vitro [15, 16] and in vivo (xenograft tumors) [15]. 
In addition, phospho-TCTP detaches from the spindle 
at the metaphase-to-anaphase transition [16]. Since the 
dynamics of spindle microtubules appear to be critical 
for spindle function, the reduction of phospho-TCTP 
may induce a disturbance of microtubule regulation with 
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Figure 5: The pharmacological inhibition of TCTP by DHA enhances the sensitivity to chemotherapy. (A) MDA cells 
were treated with 50 μM DHA for 24 h. Cell viability was measured after an additional 48 h treatment with 1 μM Doxorubicin (DOX). At 
the end of incubation time, the number of viable cells was determined by ATP-assay (upper panel) and trypan blue dye exclusion assay 
(lower panel). Data are expressed as the percentage of viable cells relative to controls. Values represent the mean ± SD, n = 4. * = p < 
0.05, *** = p < 0.001. (B) Caspase-3/7 activity (normalized to cell number) was evaluated as a marker of apoptosis. Cells were treated 
as described in the legend 5C. Data are expressed as arbitrary units. Values represent the mean ± SD, n = 4. *** = p < 0.001. (C) Western 
Blot analysis of indicated proteins in MDA cells. Cell were treated as described in the legend 5A. (D) SKBR3 cells were exposed to DHA 
(20 μM) and were then treated with 50 µg/ml of Trastuzumab (Trast) for 6 days. At the end of incubation time, the number of viable cells 
was determined by trypan blue dye exclusion assay (upper panel) and ATP-assay (lower panel). Data are expressed as the percentage of 
viable cells relative to controls. Values represent the mean ± SD, n = 5. ** = p < 0.01, *** = p < 0.001. (E) Caspase-3/7 activity (normalized 
to cell number) was evaluated as a marker of apoptosis. Cells were treated as described in the legend 5D. Data are expressed as arbitrary 
units. Values represent the mean ± SD, n = 5. *** = p < 0.001. (F) Western Blot analysis of indicated proteins in SKBR3 cells exposed to 
DHA (20 μM) and then treated with Trastuzumab for 6 days. β-actin was used as loading control.
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critical consequences for cell fate. Thus, we speculate 
that nuclear overexpression of phospho-TCTP may 
be required for proper anaphase progression in breast 
cancer cells. Our data suggest that the inhibition of 
phospho-TCTP activity by DHA can mimic spindle 
poisons in high proliferating breast cancer cells, and may 
reduce the side effects of this class of therapeutics [46].
In this context, the reduction of phospho-TCTP 
levels by DHA may represent a critical point in a sequence 
of events leading to apoptosis cell death. However, we 
cannot exclude that the antitumor effects of DHA may 
also be mediated by a more general mechanism through 
generation of ROS. In DHA-treated cells large reduction 
of the whole TCTP content by a 48 h treatment may 
also enhance DHA cytotoxicity, in accordance with our 
previously reported findings showing that TCTP is a 
critical survival factor that protects breast cancer cells 
from oxidative stress [20]. Consistent with this data, we 
observe a greater reduction of proliferating cells when 
TCTP-silenced cells were treated with DHA. Conversely, 
enforced overexpression of phopho-TCTP rescued DHA 
toxicity in TCTP-silenced HeLa cells.
Table 1: Correlation between Phospho-TCTP expression and clinicopathological characteristics in 
breast tumors
Variable phospho-TCTP expression p Value
< 1% 1–3% 4–9% ≥ 10
n(%) n(%) n(%) n(%)
Age NS(0.96)
≤ 49 2(2) 2(2) 18(21) 6(7)
50–65 2(2) 4(5) 25(29) 12(14)
≥ 66 1(1) 2(2) 7(8) 4(5)
Grade < 0.005
  I 5(6)
  II 4(5) 19(22) 4(5)
  III 4(5) 31(36) 18(21)
Lymph node 0.032
 Negative 5(6) 4(5) 32(38) 8(9)
 Positive 4(5) 18(21) 14(16)
Tumor size (cm) NS(0.16)
  ≤ 2 5(6) 5(6) 37(44) 12(14)
  > 2 3(3) 13(15) 10(12)
ER+/PgR+ 2(2) 4(5)  9(11) 1(1) 0.022
ER+/PgR− 3(4) 3(4) 10(12) 4(5)
ER−/PgR+ 3(4) 1(1)
ER−/PgR− 1(1) 28(33) 16(19)
Ki-67 0.019
 Negative 5(6) 3(4) 12(14) 5(6)
 Positive 5(6) 38(45) 17(20)
HER2 0.021
 Negative 4(5) 4(5) 21(25) 2(2)
 2+ 1(1) 2(2) 7(8) 4(5)
 3+ 2(2) 22(26) 16(19)
Abbreviations: ER, oestrogen receptor; PgR, progesterone receptor; NS non-significant.
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Figure 6: Phospho-TCTP expression is associated with high grade tumors. Representative images of the immunohistochemical 
staining of phospho-TCTP in breast cancer samples. (A) Normal human breast tissue. (B) Grade G1. (C) Grade G2. (D) Grade G3. 
(E) Positive response to trastuzumab therapy. (F) Negative response to trastuzumab therapy. Image were captured using a 20x objective. 
Bar = 100 μm
Table 2: Correlation between Phospho-TCTP expression and response to Trastuzumab therapy
Variable
phospho-TCTP expression
p Value1–3% 4–9% ≥ 10
n(%) n(%) n(%)
Response Trastuzumab-Therapy < 0.005
− 1(3) 15(43)
+ 3(9) 12(34) 4(11)
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Remarkably, we observed that MCF 10A cells 
were more protected by the DHA-induced cytotoxicity 
compared to MDA cells as suggested by the lower 
activation of caspase-3 and caspase-7. As MCF10A 
cells contain wild-type p53 [30], we can speculate an 
association between p53 activation and down regulation 
of c-Myc expression levels as a cellular response to 
the cytotoxicity of DHA. In contrast, MDA cells have 
a different molecular phenotype and express mutants 
of p53 [30, 47] and undergo apoptosis in response to 
damage induced by DHA. Therefore, DHA cytotoxicity 
is enhanced in breast cancer cells with mutated p53, i.e. 
in the more aggressive and therapeutically less responsive 
breast tumors [48].
Our data also show that TCTP and phospo-TCTP 
are present at the cell membrane. In our previous work 
we showed that TCTP-silenced MDA-MB-231 cells 
display a different morphology compared to control 
cells, suggesting that TCTP may play a critical role in 
cell shaping [20]. Consistent with this finding, it has 
been reported that TCTP possesses an actin-binding sites 
[12], moreover, Baziel et al. have proposed a critical 
cytoskeleton-mediated cellular function for TCTP [13]. 
Altogether, these findings suggest that TCTP and phospo-
TCTP may have functionally important interactions 
with microfilaments or microtubulis in a specific cell 
compartment. Further studies are necessary in order to 
clarify the implication of phospho-TCTP in cell shape 
regulation during carcinogenesis processes.
Consistent with the in vitro studies, we observed 
a clear association among phospho-TCTP levels, tumor 
grading and cell proliferation as indicated by the increase 
of Ki-67 expression. Moreover, the nuclear staining 
of phospho-TCTP was also shared by only a few cell 
clones in the primary tumor population. As tumors are 
characterized by an intratumor heterogeneity [49], the 
nuclear staining of phospho-TCTP may characterize a cell 
clone with a more aggressive phenotype and a survival 
advantage in the tumor cell compartment. Notably, we 
found an increase of phospho-TCTP levels in trastuzumab 
resistant tumors, indicating that the level of phospho-
TCTP expression is correlated with enhanced tumor 
aggressiveness.
Our data are supported by findings of Desmedt et al. 
showing that the majority of genes overexpressed in high 
grade breast cancers are associated with cell proliferation 
and cell cycle progression [50].
Finally, we provide evidence that DHA in 
combination with selected cytotoxic agents, i.e. 
Doxorubicin for triple negative and Trastuzumab for 
HER+2 positive cancers, may provide an effective 
alternative to inhibit the progression of breast cancer cells 
by regulating the phospho-TCTP function. Our results 
also suggest the possibility of lowering chemotherapeutic 
doses, in combinatorial approaches, and hence, reducing 
side effects caused by anti-cancer drugs.
In summary, this study demonstrates that nuclear 
overexpression of phospho-TCTP is correlated with 
aggressive G2–G3 tumors and suggests that phospho-
TCTP may be a prognostic marker and a therapeutic 
target. The combinatorial approach of DHA with anti-
tumor drugs suggests a novel strategy to target advanced 
breast cancer.
MATERIALS AND METHODS
Chemicals
Dihydroartemisinin were from Selleck, BI2536 from 
Selleck, Paclitaxel from Fidia Farmaceutici; Doxorubicin 
from Fidia Farmaceutici; Cisplatin/cis-Platinum (II)
Diammine Dichloride from Sigma.
Trastuzumab (Herceptin) was provided by Genen-
tech (South San Francisco, CA).
Antibodies
Antibody sources were as follows: anti-HRF/TCTP 
(MBL); anti-Phospho-TCTP (Ser46) (Cell Signaling); 
anti-c-Myc (Cell Signaling); anti-PARP (Cell Signaling); 
anti-HER2/ErbB2 (Cell Signaling); anti-cleaved caspase 
3 (Cell Signaling); anti-Ub (P4D1); anti-β-actin (Sigma-
Aldrich); anti-Lamin A/C (BD Biosciences); anti-α-
Tubulin (Sigma-Aldrich).
Cell culture and treatments
MDA-MB-231 (hereafter called MDA) (ER−, Pr−, 
Her2−), MCF7 (ER+, PR+, Her2−), SKBR3 (ER−, Pr−, 
Her2+), BT-474 (ER+, Pr+/−, /Her2+) cell lines were from 
the ICLC (Interlab Cell Line Collection, Genoa, Italy). 
HeLa cell line was from ATCC. All cell lines were 
maintained in RPMI-1640 or DMEM supplemented with 
L-glutamine, antibiotics and 10% heat-inactivated fetal 
bovine serum (FBS, all from Sigma-Aldrich) according to 
the ICLC indications. MCF 10A cell line was from ATCC. 
Cells maintained in Dulbecco’s modified Eagle’s medium 
(DMEM)/F-12 medium containing 5% horse serum, 
hydrocortisone (0.5 μg/ml), insulin (10 μg/ml), EGF (20 
ng/ml), cholera toxin (100 ng/ml), penicillin 100 units/
ml) and streptomycin (100 lg/ml) at 37°C in a 5% CO2 
humidified atmosphere. All cell lines from ICLC or ATCC 
were characterized by DNA (SRT) profiling. Cells were 
immediately expanded and frozen such that they could be 
revived every 3 to 4 months.
Cells were cultured in a humidified incubator in an 
atmosphere of 5% CO2 at 37°C. Before any experiment, 
cells were detached by mild trypsinization, washed, plated 
in complete medium and allowed to recover for 24 h.
Cells were treated with DHA (Sellekchem) or BI 
2536 (Selleckchem) dissolved in DMSO and diluted in 
culture medium immediately before use. Control media 
contained the same amount of DMSO-vehicle (<0.1%).
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Cell Viability assays
Proliferation assay
Exponentially growing cells (12 × 104 /plate) cells 
were seeded in 60 × 5 mm plates in complete medium. At 
the indicated times cells were detached with trypsin/EDTA 
and collected. Viable cells were incubated with Trypan 
blue and were counted with a haemocytometer.
ATP-assay
Exponentially growing cells (4 × 103 /well) were 
plated in triplicate in 96-well dishes. Following treatments, 
the ATP content was determined luminometrically by 
the CellTiter-Glo Luminescent Cell Viability assay, 
following the instructions of the manufacturers (Promega). 
Luminescence was measured with an automatic microtiter 
plate reader, Victor 3 V, Wallac 1420, Multilabel Counter.
Caspase-3/7 activity assay
Exponentially growing cells (4 × 103 /well) were 
plated in triplicate in 96-well dishes. Following treatments, 
cells were subjected to Caspase-3/7 activity measurement 
with Caspase-Glo 3/7 Assay (Promega). Briefly, cells 
were incubated in a cell lysis solution containing a 
luciferase substrate derivative, Ultra-GloTM Recombinant 
Luciferase for 1 hour at room temperature. The luciferase 
substrate derivative is specifically cleaved by active 
caspase-3/7 resulting in the conversion of the substrate 
into a luminescent signal (RLU). The luminescent signal 
was then normalized to cell number. Luminescence was 
measured with an automatic microtiter plate reader, Victor 
3 V, Wallac 1420, Multilabel Counter.
Western blot analysis
Cells were washed with ice-cold PBS, lysed in 
buffer contained 50 mM TRIS-HCl, pH 7.5, 150 mM 
NaCl, 1% Tryton X-100 (Sigma), 10 mM EDTA, pH 
7.2, supplemented with a protease inhibitor cocktail 
(P1860-Sigma). Aliquots (10–40 μg) from total cell lysate 
proteins were resolved on 8% or 12% SDS–PAGE gels 
and analyzed by immunoBlotting with the indicated 
antibodies followed by decoration with peroxidase-
labeled anti-rabbit (Thermo Scientific) or anti-mouse IgG 
(Dako) respectively. Blots were developed with ECL-
plus (GE Healthcare), following the instructions of the 
manufacturer.
Immunofluorescence
Cells were grown in coverslips fixed in 4% 
paraformaldehyde solution for 30 min and washed three 
times with PBS. Then, samples were permeabilized in 
0.1% Triton X-100-PBS for 10 min. After blocking with 
1% BSA, fixed cells were incubated with anti TCTP or 
anti-phospho TCTP antibodies for 1 hour and incubated 
with secondary antibody conjugated with Alexa Fluor 488 
(Molecular Probes). Images were acquired on LEICA TCS 
SP5 Confocal Laser Scanning Microscopy (CLSM, Leica 
Instruments, Mannheim, Germany).
Real-time PCR analysis
For real-time PCR analysis, total RNA was 
prepared using TRIzol and reversed transcribed using 
SuperScript reverse transcriptase (Invitrogen) following 
the instructions of the manufacturer. Real-time RT-PCR 
analysis was performed with ABI PRISM 7000 (Applied 
Biosystem), using RealMasterMix ROX (Eppendorf) to 
prepare the reaction mixes.
Primers for real-time PCR were the following:
TCTP-forward: 
5′-TGAAGAACAGAGACCAGAAAG-3′
TCTP-reverse: 
5′-CACGGTAGTCCAATAGAGCAAC-3′
GAPDH-forward: 
5′- GAAGGTGAAGGTCGGAGTC-3′
GAPDH-reverse: 
5′ CATGGGTGGAATCATATTGGAA-3′
Actin-forward:  
5′-GCGCTCAGGAGGAGCAAT-3′
Actin-reverse:  
5′-CACTCTTCCAGCCTTCC-3′.
Immunoprecipitation
Immunoprecipitations were done using 1 mg of 
protein from total cell lysates and 10 μL of polyclonal 
anti-ubiquitin antibody by incubating overnight at 4°C. 
The immune complexes were precipitated with Protein 
A-Agarose (Roche). Immunoprecipitates were resolved 
on 10% SDS-PAGE followed by Western Blotting with 
anti-TCTP antibody.
siRNA transfection using lipofectamine 
RNAiMAX
MDA-MB-231 cells were plated and grown to 70% 
confluence at 24 h. Two hours prior to transfection the 
medium was replaced with 1X Opti-MEM reduced serum 
medium (Gibco).
ON-TARGET plus Human TPT1 siRNA-smart pool 
(Dharmacon) and ON-TARGET plus Non-targeting pool 
(Dharmacon) were transfected according to the Invitrogen 
protocol using Lipofectamine RNAiMax reagent 
(Invitrogen).
Vector construction
Plasmid pcDNA3-TCTP was constructed by 
subcloning the BamHl-HindIII fragment of HrHRF/TCTP-
pRSET A plasmid containing the human TCTP ORF into 
the same sites in pcDNA3.1(-)vector. To generate the N- 
Flag-tagged pcDNA3 vector two complementary oligos 
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that introduce a FLAG cassette were annealed and ligated 
into Xhol-BamHl -cut pcDNA3 vector.
Fw: Xho-N-FLAG 5′ TCGAGATGGACTACAA 
AGACGATGACGACAAGG 3′
Rev: Bam-N-FLAG 5′GATCCCTTGTCGTCAT 
CGTCTTTGTAGTCCATC 3′
FLAG -TCTP- pcDNA3 was obtained subcloning 
the fragment BamHl-HindIII from pcDNA3-TCTP into 
the BamHl-HindIII-cut FLAG-pcDNA3 vector.
Mutagenesis
Mutagenesis of sites of phosphorylation of TCTP 
Ser46 and Ser64 was performed with QuikChange site 
directed mutagenesis kit (Stratagene) with the following 
oligos obtained from web-based program PrimerX 
(bioinformatics.org/primerx):
S46
Fw: 5′ CAGAAGGTAACATTGATGACGCCCT 
CATTGGTGGAAATGCCTCC 3′
Rev: 5′ GGAGGCATTTCCACCAATGAGGGC 
GTCATCAATGTTACCTTCTG 3′
S64
Fw: 5′ CGAGGGCGAAGGTACCGAAGCCACA 
GTAATCACTGGTGTCG 3′
Rev: 5′ CGACACCAGTGATTACTGTGGCTTC 
GGTACCTTCGCCCTCG 3′
Oligos were all synthesized by PRIMM s.r.l. 
(Milan,Italy). Oligos for mutagenesis were used to 
mutagenize FLAG-TCTP -pcDNA3.1 vector. All costructs 
were confirmed by DNA sequence analysis.
Cell transfection
HeLa cell lines stably expressing TCTP/HRF 
shRNA Plasmid or control shRNA Plasmid (Santa Cruz 
Biotechnology) vectors were selected by using puromycin 
antibiotic (1 μg/ml) 72 h after transfection. TCTP-
silenced cells were cultured in DMEM supplemented 
with puromycin dihydrochloride antibiotic, and named 
HeLa
ctrshRNA
, HeLa 
TCTPshRNA
, respectively. TCTP silenced-
cells were transiently transfected with a plasmid encoding 
Flag tagged wild-type TCTP (WT) or a mutant lacking two 
serine residues 46 and 64 (AA). Mock-transfected cells 
were used as control. All transfections were done using 
Lipofectamine Plus reagent (Invitrogen) according to the 
manufacturer’s protocols.
Evaluation of cell sensitivity to combined 
treatment
Exponentially growing cells (4 × 103/well) were 
plated in triplicate in 96-well. Cells were treated with 
DHA (20 and 50 μM), and after 24 h cell were exposed 
to treatment with DOX (0.1, 1 and 5 μM), or Trastuzumab 
(50 and 100 μg/ml) alone or in combination at various 
ratio. Growth inhibition was calculated as the percentage 
of viable cells compared with untreated cells by ATP 
assay. The CompuSyn software program was used to 
calculated synergistic, additive or antagonistic effects as a 
non-constant ratio combination. The CompuSyn software 
is based on the Median-Effect Principle (Chou) and the 
Combination Index-Isobologram Theorem (Chou-Talalay).
The combination index (CI) indicates a quantitative 
measure of the degree of drug interaction in terms of 
synergistic (CI < 1), additive (CI = 1) or antagonistic 
effect (CI > 1).
Patients
Eighty-five cases of breast cancer were retrieved 
from the files of the Department of Pathology, at the 
National Cancer Istitute in Milan, Italy. The cases were 
selected according the patient clinical stage, histologic 
grade, and ER, PgR HER2 status. Ki-67 stains were also 
available in all cases. Tumors were scored ER and PgR 
positive when ≥ 10% of the nuclei were positive. HER2 
was evaluated as 0, 1+, 2+, or 3+ according to ASCO/
CAP guidelines (2013). All 2+ cases were evaluated by 
chromogenic in situ hybridization (CISH) to measure 
HER2 amplification. The cut-off for a “high” Ki-67 
labeling index was ≥ 20% of positive tumor nuclei. Stage 
was determined according to UICC criteria [51]. Table 
1 lists the clinico-pathologic characteristics of patients. 
Before undergoing routine surgery, all patients signed 
an informed consent authorizing the Institute to utilize 
their removed biological tissues for research purposes. 
Institutional approval from our Ethics Committee was 
obtained for the conduct of the study.
Immunohistochemistry and CISH
Immunohistochemistry was performed by the 
standard biotin–streptavidin-peroxidase method on 3 μm-
thick formalin-fixed, paraffin-embedded tissue sections. 
After deparaffinization in xylene and rehydration in 
descending concentrations of alcohol, an antigen retrieval 
step was performed by autoclave in 10 mM citrate buffer 
(pH 6). Endogenous peroxidase was blocked by 3% 
hydrogen peroxide. After blocking with Peroxidase-
Blocking reagent for 5 min, the sections were incubated 
with the diluted primary antibody testing for the 
following markers: ER and PgR expression using 1D5 
and PgR636 monoclonal antibodies (Dako), respectively; 
tumor proliferation using MIB1 monoclonal antibody 
(DAKO); HER2 oncoprotein overexpression using 
HercepTest (Dako), and polyclonal antibody pTCTP (Cell 
Signaling). The immunoreactivity was detected by using 
LSAB+ Kit (Dako) in room temperature according to the 
manufacturer’s instructions. The 3,3-diaminobenzidine 
(DAB) (Liquid DAB+; Dako) solution was used as a 
chromogen. Sections were lightly counterstained with 
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hematoxylin. The section without primary antibody 
served as negative control. Phospho TCTP expression was 
evaluated in each case as ≤ 1%, 1%–3%, 4–9%, ≥ 10%, of 
the tumor cells expressed nuclear phospho-TCTP.
For CISH staining procedures, sections were 
deparaffinized and heated in a 1M NaCNS solution 
95°C for 10 minutes. After two 5-minute washes at 4°C 
in distilled water, the slides were incubated with 3 to 10 
μg/ml proteinase K (EC 3.4.21.64) (Sigma, St.Louis, 
MO) for 10 to 15 minutes at 37°C. The slides were then 
washed (twice at 5 minutes each, at 4°C) in distilled 
water, dehydrated with graded ethanols, and air dried. 
The digoxigenin-labeled HER2 probe (double-stranded) 
(Zymed Laboratories Inc.) was applied to the slides, 
covered with coverslips, and denatured at 96°C for 6 
minutes on a heat block. Hybridization was performed 
overnight at 37°C in a humid chamber. The slides were 
then washed for 5 minutes with 0.5 x standard saline citrate 
at 75°C, followed by a brief rinsing in phosphate buffered 
saline/0.25% Tween20. Immunodetection was performed 
according to the manufacturer’s instructions. Finally, 
sections were lightly counterstained with hematoxylin.
Statistical analysis
All experiments were done at least three times 
unless otherwise indicated. The results are presented 
as means ± SD. One-way ANOVA followed by the 
Bonferroni’s test using the PRISM GraphPad software 
was used in the analysis of three or more data sets. 
Differences were considered to be significant for 
P < 0.05 and highly significant for P < 0.01 and P < 0.001. 
Association between phospho-TCTP expression and 
clinico-pathological parameters in breast cancer patients 
was analysed using the Chi-square test.
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